Quality by design in formulation and process development for a freeze-dried, small molecule parenteral product: a case study

Authors:
  • TPTimothy W. Paul
    Timothy W. Paul
  • NPNathan A. Pease
    Nathan A. Pease
  • NHNancy J. Harper
    Nancy J. Harper
  • PBPrabir K. Basu
    Prabir K. Basu
  • EOElizabeth A. Oslos
    Elizabeth A. Oslos
  • GSGregory A. Sacha
    Gregory A. Sacha
  • WKWei Y. Kuu
    Wei Y. Kuu
  • LHLisa M. Hardwick
    Lisa M. Hardwick
  • JKJacquelyn J. Karty
    Jacquelyn J. Karty
  • MPMichael J. Pikal
    Michael J. Pikal
  • EHEun Hee
    Eun Hee
Publisher website
Google Scholar
Abstract
A case study has been developed to illustrate one way of incorporating a Quality by Design approach into formulation and process development for a small molecule, freeze-dried parenteral product. Sodium ethacrynate was chosen as the model compound. Principal degradation products of sodium ethacrynate result from hydrolysis of the unsaturated ketone in aqueous solution, and dimer formation from a Diels–Alder condensation in the freeze-dried solid state. When the drug crystallizes in a frozen solution, the eutectic melting temperature is above −5°C. Crystallization in the frozen system is affected by pH in the range of pH 6–8 and buffer concentration in the range of 5–50 mM, where higher pH and lower buffer concentration favor crystallization. Physical state of the drug is critical to solid state stability, given the relative instability of amorphous drug. Stability was shown to vary considerably over the ranges of pH and buffer concentration examined, and vial-to-vial variability in degree of crystallinity is a potential concern. The formulation design space was constructed in terms of pH and drug concentration, and assuming a constant 5 mM concentration of buffer. The process design space is constructed to take into account limitations on the process imposed by the product and by equipment capability.

This publication has 9 references indexed in Scilit: